Drug discovery and development is a complex and lengthy process. It requires creativity, tenacity, agility and the expertise of thousands of scientists working diligently toward our goal to save and improve lives around the world.
Drug discovery and development
We’re focused on transforming novel science into groundbreaking medicines and vaccines for the people who need them. Our teams of scientists bring together diverse expertise and backgrounds, combined with cutting-edge technologies and tools, to help discover the next scientific breakthrough for patients.
Drug discovery: From hit to lead
ww5 scientists explain how new technologies can accelerate the drug discovery process as we use the power of leading-edge science to save and improve lives. Learn more
Analytical R&D: Partners in problem solving
Our talented scientists in our analytical research & development team are integrating state-of-the-art physical, analytical and bioanalytical solutions, and applying innovative technologies, to advance our company’s pipeline.
Formulation development: Putting the patient first
Our formulation development team explains how leading with a patient-centric approach helps advance our understanding of formulation design, material science and engineering to improve the patient experience.
Translational medicine: Bridging scientific potential and clinical impact
Our scientists are using translational medicine to help guide decision-making in the drug development process. By leveraging state-of-the-art capabilities, including biomarker development, quantitative modeling and advanced imaging techniques, they can generate insights that drive critical decisions and help advance promising candidates through our pipeline. Learn more
Business development: Accelerating bold science together
With a robust pipeline and portfolio fueled by discoveries made inside and outside of our walls, we know that collaborations are critical to advancing science as part of the drug discovery process. Learn more
Clinical supply and manufacturing: Serving patients worldwide
Our clinical supply and pharmaceutical operations teams explain the importance of staying current with trends and advancing technology for optimal clinical trials and patient outcomes.
From lab to patient: explore the journey of a molecule
Drug discovery and development involves dedication and commitment from a wide range of people — from scientists, data analysts and clinical trial volunteers to manufacturing, regulatory, development, marketing and commercial teams, among many others.
Discovery is the process of exploring new and unique molecules, compounds and biologics that may have the potential to treat or prevent disease. We consider variables such as disease prevalence, unmet medical needs and current treatment options when identifying a preclinical candidate (PCC).
It takes about 10 years for a new product to reach the marketplace after the initial discovery.
During this phase, the active pharmaceutical ingredient is produced to create the material that will be supplied for the clinical studies.
1 in every 5,000 compounds that enter discovery and progress to preclinical development actually become an approved drug.
Clinical studies determine the safety and efficacy of our products by gathering evidence through testing and analysis in trial volunteers — first in healthy volunteers, then in those with the disease. Once we have sufficient safety and efficacy data, we file an application with the information we know about the product — including study data, analyses and reports — with a regulatory agency (such as the U.S. Food and Drug Administration) for approval.
Less than 12% of investigational medicines that enter clinical testing make it to approval.
Manufacturing is the process of industrial-scale production, packaging and distribution of our medicines and vaccines. The process varies from product to product but is always in full compliance with all regulations and Good Manufacturing Practices (GMPs, also referred to as "cGMPs" or "current GMPs") to ensure a compliant, reliable supply for our patients.
GMP regulations outline the minimum quality standards for manufacturing and vary by country. Each country has its own agency to monitor meeting the regulations and requirements.
Once a product is approved and manufactured, we promote it — through education and awareness campaigns — to customers, including physicians, health care providers, pharmacies, patient populations, wholesalers and governments. With a customer- and data-focused approach, we develop a brand strategy to create a unique impression for each product.
Marketing teams are key to creating the campaigns to educate stakeholders (customers) about the efficacy and safety of our products to ensure appropriate use.
Post-marketing begins when the medicine or vaccine is released to the market. It includes activities to monitor and evaluate the product for safety and efficacy in a real-world setting.
Companies monitor approved medicines for as long as they are on the market. This meets regulatory reporting requirements, provides internal reporting for ongoing analyses and supplies data to support the safety of the product.
Clinical trials are a key part of the drug development process, testing the safety and effectiveness of medicines and vaccines in development and exploring how different people’s bodies respond to them. Ensuring our data represents varied backgrounds advances science and improves lives by reflecting the true diversity of the populations we aim to serve.
Forward-Looking Statement of ww5 & Co., Inc., Rahway, N.J., USA
This website of ww5 & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.
